Internship

Vertex Summer 2025 Intern

Clinical Data Management & Metrics

Confirmed live in the last 24 hours

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

Compensation Overview

$20 - $50/hr

No H1B Sponsorship

Boston, MA, USA

Category
Data Management
Data Analysis
Data & Analytics
Required Skills
Data Analysis
Requirements
  • Enrolled in an undergraduate or graduate program
  • Majors in Biotechnology, Data Analytics, Engineering or Life Sciences related field, or a related field of study
  • Permanent legal authorization to work in the United States
  • Candidate must be enrolled in an advanced degree program if graduating before May 2025
  • Candidate must be available to work full-time, 40 hours per week from May - August 2025
Responsibilities
  • Responsible for the clinical data strategy for all studies, programs, phases and therapeutic areas
  • Focus on learning the nuances of data analysis in a clinical trial setting
  • Help to revise the structure of the team Sharepoint site, consolidating information and making it more accessible
  • Updating country intelligence repository, QCing documents for IRB/EC submissions and filing said documents in the Trial Master File
  • Partner with a clinical program lead to refine processes across functions
  • Support ongoing department standardization and document development initiatives
  • Support the RBSM applications validation activities and continuous improvement of the risk-based study management process
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • Vertex's partnership with Orna could lead to breakthroughs in gene therapy solutions.
  • Recent investments indicate strong investor confidence in Vertex's strategic direction.
  • Vertex's reaffirmed stock rating suggests stability and potential for steady growth.

What critics are saying

  • Increased competition in cystic fibrosis treatments could impact Vertex's market share.
  • High costs of gene-editing therapies may limit their commercial success.
  • Regulatory challenges could delay approvals for Vertex's new gene-editing therapies.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on transformative medicines for serious diseases, like cystic fibrosis.
  • Partnerships with Arbor and Orna enhance Vertex's gene-editing and cell therapy capabilities.
  • Vertex's innovative R&D approach sets it apart in the biotechnology industry.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

Slater Sentinel
Mar 23rd, 2025
Stevens Capital Management LP Makes New $829,000 Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Stevens Capital Management LP makes new $829,000 investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Investing.com
Mar 20th, 2025
BMO maintains Vertex stock Market Perform rating and $41 target

The reaffirmation of the rating and target came after Vertex held its first analyst day since its initial public offering in 2020.

Stat News
Mar 18th, 2025
Genetics expert is first NIH director to leave under Trump

He will be replaced on an interim basis by Director Ian Smith, a former Vertex Pharmaceuticals executive.

GlobeNewswire
Mar 18th, 2025
Arbor Biotechnologies Announces $73.9 Million Series C Financing to Advance Novel Gene Editing Therapeutics

Series C led by ARCH Venture Partners and TCGX with significant participation from existing and new investors Financing extends Arbor’s cash runway into...

MarketBeat
Feb 14th, 2025
JSF Financial LLC Invests $751,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

JSF Financial LLC invests $751,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).